{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:34:54Z","timestamp":1782311694826,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00120-025-02555-z","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:49:26Z","timestamp":1742489366000},"page":"595-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aktive \u00dcberwachung des Prostatakarzinoms","Active surveillance of prostate cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Christian","family":"Bolenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schimm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2555_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA et\u00a0al (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N\u00a0Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"2555_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","volume":"77","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian\u00a0JJ, Mamawala\u00a0M, Epstein\u00a0JI et\u00a0al (2020) Active Surveillance of Grade Group\u00a01 Prostate Cancer: Long-term Outcomes from a\u00a0Large Prospective Cohort. Eur Urol 77:675\u2013682","journal-title":"Eur Urol"},{"key":"2555_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cncr.20855","volume":"103","author":"G Aus","year":"2005","unstructured":"Aus\u00a0G, Robinson\u00a0D, Rosell\u00a0J et\u00a0al (2005) Survival in prostate carcinoma\u2014outcomes from a\u00a0prospective, population-based cohort of 8887 men with up to 15\u00a0years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 103:943\u2013951","journal-title":"Cancer"},{"key":"2555_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","volume":"364","author":"A Bill-Axelson","year":"2011","unstructured":"Bill-Axelson\u00a0A, Holmberg\u00a0L, Ruutu\u00a0M et\u00a0al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N\u00a0Engl J Med 364:1708\u20131717","journal-title":"N Engl J Med"},{"key":"2555_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0022-5347(17)35487-3","volume":"150","author":"WA Sakr","year":"1993","unstructured":"Sakr\u00a0WA, Haas\u00a0GP, Cassin\u00a0BF et\u00a0al (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J\u00a0Urol 150:379\u2013385","journal-title":"J Urol"},{"key":"2555_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00120-023-02197-z","volume":"63","author":"C Kowalski","year":"2024","unstructured":"Kowalski\u00a0C, Sibert\u00a0NT, Hammerer\u00a0P et\u00a0al (2024) Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers. Urologie 63:67\u201374","journal-title":"Urologie"},{"key":"2555_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam\u00a0TBL, Maclennan\u00a0S, Willemse\u00a0PM et\u00a0al (2019) EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol 76:790\u2013813","journal-title":"Eur Urol"},{"key":"2555_CR8","doi-asserted-by":"crossref","unstructured":"Boschheidgen M, Schimmoller L, Radtke JP et\u00a0al (2024) MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group\u00a01 prostate cancer. Eur Radiol","DOI":"10.1007\/s00330-024-11062-2"},{"key":"2555_CR9","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1001\/jama.2024.6695","volume":"331","author":"LF Newcomb","year":"2024","unstructured":"Newcomb\u00a0LF, Schenk\u00a0JM, Zheng\u00a0Y et\u00a0al (2024) Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA 331:2084\u20132093","journal-title":"JAMA"},{"key":"2555_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/pros.20648","volume":"67","author":"R Choo","year":"2007","unstructured":"Choo\u00a0R, Danjoux\u00a0C, Morton\u00a0G et\u00a0al (2007) How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score\u00a04\u20137, clinically localized prostate cancer? Prostate 67:1614\u20131620","journal-title":"Prostate"},{"key":"2555_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.juro.2008.11.107","volume":"181","author":"SL Conti","year":"2009","unstructured":"Conti\u00a0SL, Dall\u2019era\u00a0M, Fradet\u00a0V et\u00a0al (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J\u00a0Urol 181:1628\u20131633 (discussion 1633\u20131624)","journal-title":"J Urol"},{"key":"2555_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/j.1464-410X.2009.08597.x","volume":"104","author":"M Louie-Johnsun","year":"2009","unstructured":"Louie-Johnsun\u00a0M, Neill\u00a0M, Treurnicht\u00a0K et\u00a0al (2009) Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically. BJU Int 104:1501\u20131504","journal-title":"BJU Int"},{"key":"2555_CR13","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.23827","volume":"113","author":"N Suardi","year":"2008","unstructured":"Suardi\u00a0N, Capitanio\u00a0U, Chun\u00a0FK et\u00a0al (2008) Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 113:2068\u20132072","journal-title":"Cancer"},{"key":"2555_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA et\u00a0al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N\u00a0Engl J Med 375:1415\u20131424","journal-title":"N Engl J Med"},{"key":"2555_CR15","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1016\/j.clgc.2020.05.008","volume":"18","author":"D Enikeev","year":"2020","unstructured":"Enikeev\u00a0D, Morozov\u00a0A, Taratkin\u00a0M et\u00a0al (2020) Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes. Clin Genitourin Cancer 18:e739\u2013e753","journal-title":"Clin Genitourin Cancer"},{"key":"2555_CR16","first-page":"617","volume":"5","author":"M Baboudjian","year":"2022","unstructured":"Baboudjian\u00a0M, Breda\u00a0A, Rajwa\u00a0P et\u00a0al (2022) Active Surveillance for Intermediate-risk Prostate Cancer: A\u00a0Systematic Review, Meta-analysis, and Metaregression. Eur Urol 5:617\u2013627","journal-title":"Eur Urol"},{"key":"2555_CR17","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","volume":"34","author":"RC Chen","year":"2016","unstructured":"Chen\u00a0RC, Rumble\u00a0RB, Loblaw\u00a0DA et\u00a0al (2016) Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J\u00a0Clin Oncol 34:2182\u20132190","journal-title":"J Clin Oncol"},{"key":"2555_CR18","first-page":"30","volume":"59","author":"B Valentin","year":"2024","unstructured":"Valentin\u00a0B, Arsov\u00a0C, Ullrich\u00a0T et\u00a0al (2024) Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group\u00a01 or\u00a02 Prostate Cancer: The Prospective PROMM-AS Study. Eur Urol 59:30\u201338","journal-title":"Eur Urol"},{"key":"2555_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/his.13888","volume":"75","author":"DM Berney","year":"2019","unstructured":"Berney\u00a0DM, Beltran\u00a0L, Sandu\u00a0H et\u00a0al (2019) The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death. Histopathology 75:589\u2013597","journal-title":"Histopathology"},{"key":"2555_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","volume":"69","author":"G Sauter","year":"2016","unstructured":"Sauter\u00a0G, Steurer\u00a0S, Clauditz\u00a0TS et\u00a0al (2016) Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. Eur Urol 69:592\u2013598","journal-title":"Eur Urol"},{"key":"2555_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.humpath.2007.01.006","volume":"38","author":"RA Marks","year":"2007","unstructured":"Marks\u00a0RA, Koch\u00a0MO, Lopez-Beltran\u00a0A et\u00a0al (2007) The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol 38:1207\u20131211","journal-title":"Hum Pathol"},{"key":"2555_CR22","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.juro.2015.04.113","volume":"194","author":"DM Moreira","year":"2015","unstructured":"Moreira\u00a0DM, Fleshner\u00a0NE, Freedland\u00a0SJ (2015) Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. J\u00a0Urol 194:1258\u20131263","journal-title":"J Urol"},{"key":"2555_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2014.284","volume":"1","author":"AC Raldow","year":"2015","unstructured":"Raldow\u00a0AC, Zhang\u00a0D, Chen\u00a0MH et\u00a0al (2015) Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol 1:334\u2013340","journal-title":"JAMA Oncol"},{"key":"2555_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz\u00a0L, Vesprini\u00a0D, Sethukavalan\u00a0P et\u00a0al (2015) Long-term follow-up of a\u00a0large active surveillance cohort of patients with prostate cancer. J\u00a0Clin Oncol 33:272\u2013277","journal-title":"J Clin Oncol"},{"key":"2555_CR25","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cncr.23502","volume":"112","author":"MA Dall\u2019era","year":"2008","unstructured":"Dall\u2019era\u00a0MA, Konety\u00a0BR, Cowan\u00a0JE et\u00a0al (2008) Active surveillance for the management of prostate cancer in a\u00a0contemporary cohort. Cancer 112:2664\u20132670","journal-title":"Cancer"},{"key":"2555_CR26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.juro.2008.11.109","volume":"181","author":"SE Eggener","year":"2009","unstructured":"Eggener\u00a0SE, Mueller\u00a0A, Berglund\u00a0RK et\u00a0al (2009) A multi-institutional evaluation of active surveillance for low risk prostate cancer. J\u00a0Urol 181:1635\u20131641 (discussion 1641)","journal-title":"J Urol"},{"key":"2555_CR27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1464-410X.2009.08887.x","volume":"105","author":"RC Van Den Bergh","year":"2010","unstructured":"Van Den Bergh\u00a0RC, Vasarainen\u00a0H, Van Der Poel\u00a0HG et\u00a0al (2010) Short-term outcomes of the prospective multicentre \u2018Prostate Cancer Research International: Active Surveillance\u2019 study. BJU Int 105:956\u2013962","journal-title":"BJU Int"},{"key":"2555_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","volume":"70","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst\u00a0LP, Valdagni\u00a0R, Rannikko\u00a0A et\u00a0al (2016) A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a\u00a0switch to active treatment. Eur Urol 70:954\u2013960","journal-title":"Eur Urol"},{"key":"2555_CR29","first-page":"3","volume":"0","author":"Deutsche Krebsgesellschaft","year":"2024","unstructured":"Deutsche Krebsgesellschaft (2024) Leitlinie Prostatakarzinom, Langversion 7. Awmf 0:3 (In)","journal-title":"Awmf"},{"key":"2555_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","volume":"77","author":"L Klotz","year":"2020","unstructured":"Klotz\u00a0L, Pond\u00a0G, Loblaw\u00a0A et\u00a0al (2020) Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2\u2011year Postbiopsy Follow-up. Eur Urol 77:311\u2013317","journal-title":"Eur Urol"},{"key":"2555_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","volume":"81","author":"PM Willemse","year":"2022","unstructured":"Willemse\u00a0PM, Davis\u00a0NF, Grivas\u00a0N et\u00a0al (2022) Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. Eur Urol 81:337\u2013346","journal-title":"Eur Urol"},{"key":"2555_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2015.20","volume":"18","author":"R Guo","year":"2015","unstructured":"Guo\u00a0R, Cai\u00a0L, Fan\u00a0Y et\u00a0al (2015) Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a\u00a0diagnostic meta-analysis. Prostate Cancer Prostatic Dis 18:221\u2013228","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2555_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/pcan.2016.16","volume":"19","author":"JP Radtke","year":"2016","unstructured":"Radtke\u00a0JP, Kuru\u00a0TH, Bonekamp\u00a0D et\u00a0al (2016) Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis 19:283\u2013291","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2555_CR34","doi-asserted-by":"crossref","unstructured":"Englman C, Maffei D, Allen C et\u00a0al (2024) PRECISE Version\u00a02: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol","DOI":"10.1016\/S0302-2838(24)01391-5"},{"key":"2555_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","volume":"71","author":"CM Moore","year":"2017","unstructured":"Moore\u00a0CM, Giganti\u00a0F, Albertsen\u00a0P et\u00a0al (2017) Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations\u2014A Report of a\u00a0European School of Oncology Task Force. Eur Urol 71:648\u2013655","journal-title":"Eur Urol"},{"key":"2555_CR36","first-page":"537","volume":"5","author":"CE Chu","year":"2022","unstructured":"Chu\u00a0CE, Cowan\u00a0JE, Lonergan\u00a0PE et\u00a0al (2022) Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol 5:537\u2013543","journal-title":"Eur Urol"},{"key":"2555_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/MOU.0000000000000397","volume":"27","author":"IG Schoots","year":"2017","unstructured":"Schoots\u00a0IG, Moore\u00a0CM, Rouviere\u00a0O (2017) Role of MRI in low-risk prostate cancer: finding the wolf in sheep\u2019s clothing or the sheep in wolf\u2019s clothing? Curr Opin Urol 27:238\u2013245","journal-title":"Curr Opin Urol"},{"key":"2555_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford\u00a0P, Van Den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I:\u00a0Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2555_CR39","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00330-021-08332-8","volume":"32","author":"M Boschheidgen","year":"2022","unstructured":"Boschheidgen\u00a0M, Schimmoller\u00a0L, Arsov\u00a0C et\u00a0al (2022) MRI grading for the prediction of prostate cancer aggressiveness. Eur Radiol 32:2351\u20132359","journal-title":"Eur Radiol"},{"key":"2555_CR40","first-page":"227","volume":"4","author":"LP O\u2019connor","year":"2021","unstructured":"O\u2019connor\u00a0LP, Wang\u00a0AZ, Yerram\u00a0NK et\u00a0al (2021) Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. Eur Urol 4:227\u2013234","journal-title":"Eur Urol"},{"key":"2555_CR41","first-page":"231","volume":"1","author":"TFW Soeterik","year":"2018","unstructured":"Soeterik\u00a0TFW, Van Melick\u00a0HHE, Dijksman\u00a0LM et\u00a0al (2018) Active Surveillance for Prostate Cancer in a\u00a0Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients. Eur Urol 1:231\u2013237","journal-title":"Eur Urol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02555-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:04:05Z","timestamp":1748955845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02555-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"5 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Autoren sind Mitglieder der Leitliniengruppe zur Erstellung der S3-Leitlinie Prostatakarzinom im Rahmen des Leitlinienprogrammes Onkologie der Deutschen Krebsgesellschaft, der Deutschen Krebshilfe und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). C.\u00a0Bolenz: A.\u00a0Finanzielle Interessen: Referentenhonorare: AstraZeneca GmbH, Bayer AG, Bristol-Myers Squibb, Johnson & Johnson; Reisekosten: Johnson & Johnson. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: \u00c4rztlicher Direktor der Klinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Ulm | Vorstandsmitglied der Deutschen Gesellschaft f\u00fcr Urologie (Ressort Haushalt und Finanzen) | Mitglied der Leitliniengruppe zur Erstellung der S3-Leitlinie Prostatakarzinom im Rahmen des Leitlinienprogrammes Onkologie der Deutschen Krebsgesellschaft, der Deutschen Krebshilfe und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). M.-O.\u00a0Grimm: A.\u00a0Finanzielle Interessen: Durchf\u00fchrung klinischer Studien (TITAN RCC, TITAN TCC) von Bristol-Myers Squibb, Forschungsunterst\u00fctzung Intuitive Surgical \u2013randomisierte Studie zum Vergleich roboterassistierte vs. offene partielle Nephrektomie (OPERA), ARASAFE-Studie, Forschungsunterst\u00fctzung durch Bayer HealthCare. \u2013\u00a0Referentenhonorare inklusive Erstattung evtl. angefallener Reisekosten: Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer.\u00a0\u2013 Beratungshonorare: Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, EUSA, Gilead, Hexal, Ipsen, Janssen, Kranus Health, Merck Serono, MSD, Novartis, Pfizer, Takeda, Telix. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Direktor Urologische Klinik und Poliklinik, Universit\u00e4tsklinikum Jena | Mitgliedschaften: Dt. Gesellschaft f\u00fcr Urologie, European Association of Urology | Executive Board ESOU | Leiter der Steuergruppe S3-Leitlinie Prostatakarzinom. A.\u00a0Heidenreich: A.\u00a0Finanzielle Interessen: A.\u00a0Heidenreich gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Klinikdirektor, Klinik f\u00fcr Urologie, Uniklinik K\u00f6ln | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie, American Association of Urology, American Society of Clinical Oncology, European Association of Urology, Society of Urological Oncology, Societe Internal d\u2019Urologie. G.\u00a0Kristiansen: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Novartis Pharma GmbH, \u00c4rztliche Akademie f\u00fcr medizinische Fort- und Weiterbildung in Nordrhein, Janssen Pharmaceutica NV, Landeskrebsregister NRW gGmbH, Jansen-Cilag GmbH, Solution akademie GmbH, \u00c4rztliche Akademie f\u00fcr medizinische Fort- und Weiterbildung in Nordrhein, Einrichtung der \u00c4rztekammer Nordrhein, MSD Sharp & Dohme GmbH, PathoTres; Gemeinschaftspraxis f\u00fcr Pathologie, AstraZeneca GmbH, Med publico GmbH, Institut f\u00fcr Qualit\u00e4tssicherung und Transparenz im Gesundheitswesen (IQTIG), PROMEDICIS GmbH, Astellas Pharma. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Institutsdirektor, Institut f\u00fcr Pathologie, Venusberg-Campus\u00a01, Geb. C\u00a062, 53127 Bonn | Universit\u00e4tsklinikum Bonn (A\u00f6R), Institutsdirektor (UKB) | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pathologie (DGP), Bundesverband Deutscher Pathologen e.\u202fV. (BDP), Internationale Akademie f\u00fcr Pathologie (IAP), Internationale Gesellschaft f\u00fcr Urologische Pathologie (ISUP), Europ\u00e4isches Netzwerk f\u00fcr Uropathologie (ENUP), Deutsches Prostatakarzinom Konsortium (DPKK). L.\u00a0Schimm\u00f6ller: A.\u00a0Finanzielle Interessen: Kostenerstattung Vortragst\u00e4tigkeiten B.e. academy, Beckelmann, Bayer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Radiologe, Klinikdirektor, Institut f\u00fcr Diagnostische, Interventionelle Radiologie und Nuklearmedizin, Marien Hospital Herne, Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum; Angestellter Radiologe, Wissenschaftlicher Mitarbeiter, Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum D\u00fcsseldorf | Mitgliedschaften: DRG, ESR, RSNA, DeGIR, ESOI. S.\u00a0Schmidt: A.\u00a0Finanzielle Interessen: Diese Arbeit basiert auf der Aktualisierung der S3-Leitlinie Prostatakarzinom, f\u00fcr welche Drittmittelgelder beantragt und bewilligt wurden (Personal- und Sachausgaben, institutionelle F\u00f6rderung). \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellte der Deutschen Gesellschaft f\u00fcr Urologie e.\u202fV., Teamleitung UroEvidence der DGU. M.\u00a0Schostak: A.\u00a0Finanzielle Interessen: M.\u00a0Schostak gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00c4rztlicher Leiter bei  (keine Klinik oder Praxis) | Mitgliedschaften: DGU, EAU | Vorsitzender des AK f\u00fcr fokale und Mikrotherapie der Akademie der DGU. B.\u00a0Hadaschik: A.\u00a0Finanzielle Interessen: Klinische Studien (IITs): AAA\/Novartis, Bristol-Myers Squibb, Amgen, Deutsche Krebshilfe. \u2013\u00a0Vortragshonorare, Reiseunterst\u00fctzung: ABX, Accord, Amgen, Astellas, AstraZeneca, Bayer, Janssen R&D, Johnson&Johnson, Lightpoint, MSD, Pfizer, Novartis.\u00a0\u2013 Janssen, Bayer, ABX, Lightpoint, Amgen, MSD, Pfizer, Novartis. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Direktor Klinik f\u00fcr Urologie, UK Essen; Vizedirektor WTZ Essen | Organgruppensprecher Prostatakarzinom der AUO der DKG | Vorstandsmitglied DGU\u00a0\u2013 Ressort Fort- und Weiterbildung | Mitglied DKH, Ausschuss Krebs-Pr\u00e4vention und -Fr\u00fcherkennung.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}